Inflammatory bowel disease (IBD) is a chronic condition that includes two main types, Crohn’s disease (CD) and ulcerative colitis (UC), involving inflammation of the gastrointestinal (GI) tract. The exact cause of IBD is unknown but could be a combination of genetic, environmental, and immune system factors. This study investigated the impact of IBD on microbiota diversity by evaluating the differences in microbial composition and the microbiota of a control group (A) of healthy individuals and a group (B) of IBD patients. Sixty biopsies were collected from participants recruited from hospitals in Makkah, Saudi Arabia. Biopsy specimens were taken during colonoscopy examination, and bacterial identification was performed by extracting ribosomal DNA from sigmoid colon biopsies using a DNeasy Blood & Tissue Kit. Metagenomics and bioinformatics analyses were then conducted to analyze and compare the microbiota in the two groups. The results showed that the varieties of core microbiome species were 3.81% greater in the IBD patients than in the members of the control group. Furthermore, the differences between the groups were significantly greater than the variations within each group. Differences between the two groups were detected in the relative abundance of Clostridium nexile, Ruminococcus gnavus, Ruminococcus faecis, and Escherichia coli. These results indicate that microbiota could play a role in the pathogenesis of IBD and suggest that microbial diversity can serve as a biomarker for diagnosing the disease and monitoring its progression.
17 January 2026 in Journal of Nanoparticle Research
Background Graphene-based nanomaterials are increasingly explored for cancer diagnosis and therapy, yet a comprehensive mapping of their scholarly landscape is lacking. Methods On 13 March 2025, a total of 4917 records (2016–2025) were retrieved from the Scopus database using a multistep search strategy. Bibliometric indicators were analyzed with Bibliometrix (R-package), VOSviewer, and CiteSpace to evaluate research growth, collaboration, intellectual structures, and thematic evolution. Results Publications grew at an annual rate of 2.97%, with China leading in both productivity and citations. Bradford’s Law identified 21 core journals, and leading contributors included LI Y and ZHANG Y. Collaboration networks showed dense interinstitutional and international links, particularly across Asia. Keyword and thematic analyses highlighted enduring focuses such as “graphene oxide,” “drug delivery,” and “biosensors,” while emerging trends included “plasmon resonance biosensor,” “brain tumor detection,” and advanced therapeutic applications. Co-citation and overlay mapping revealed conceptual shifts toward precision diagnostics and targeted therapies. Conclusion This study provides the first integrated bibliometric roadmap of graphene-based cancer research (2016–2025), outlining its growth trajectory, knowledge structures, and evolving themes. Findings inform researchers, funding agencies, and policymakers on current strengths, translational challenges, and priority directions for advancing graphene-based innovations in oncology.